Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century ...

Acquisition provides access to critical resources encompassing a biobank of more than 150,000 tumor specimens, 200,000 ...

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ...

In the span of eight months, Big Pharma companies took over four of the hottest radiopharmaceutical players in the industry.

Mural nominated two new development candidates, MURA-8518 a novel binding protein-resistant IL-18 with half-life extension, ...

Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held ...

Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

For the fifth consecutive year, Congress has adjourned and allowed Medicare cuts,” said Bruce A. Scott, MD, president of the AMA.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

We recently compiled a list of the 12 Best Penny Stocks to Invest in According to the Media. In this article, we are going to ...

On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...